The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 26, 2021

Filed:

May. 10, 2019
Applicant:

Enlitic, Inc., San Francisco, CA (US);

Inventors:

Kevin Lyman, Fords, NJ (US);

Anthony Upton, Malvern, AU;

Li Yao, San Francisco, CA (US);

Ben Covington, Berkeley, CA (US);

Keith Lui, San Francisco, CA (US);

Assignee:

Enlitic, Inc., San Francisco, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G16H 30/20 (2018.01); G16H 10/20 (2018.01); G06N 20/00 (2019.01); G06F 9/54 (2006.01); G06N 5/04 (2006.01); G16H 10/60 (2018.01); H04L 29/06 (2006.01); G16H 30/40 (2018.01); G16H 15/00 (2018.01); G06K 9/62 (2006.01); G06T 5/00 (2006.01); G06T 5/50 (2006.01); G06T 7/00 (2017.01); G06T 11/00 (2006.01); G06T 7/187 (2017.01); G06T 7/11 (2017.01); G06F 3/0482 (2013.01); G06T 3/40 (2006.01); A61B 5/00 (2006.01); G16H 50/20 (2018.01); G06F 21/62 (2013.01); G06Q 20/14 (2012.01); G16H 40/20 (2018.01); G06F 3/0484 (2013.01); G06Q 10/06 (2012.01); G06T 7/10 (2017.01); G06T 11/20 (2006.01); G06F 16/245 (2019.01); G06T 7/44 (2017.01); G06N 20/20 (2019.01); G06K 9/20 (2006.01); H04L 29/08 (2006.01); G16H 50/70 (2018.01); G06T 7/70 (2017.01); G16H 50/30 (2018.01); A61B 5/055 (2006.01); A61B 6/03 (2006.01); A61B 8/00 (2006.01); G06K 9/66 (2006.01); A61B 6/00 (2006.01); G06Q 50/22 (2018.01); G06F 40/295 (2020.01);
U.S. Cl.
CPC ...
G16H 10/60 (2018.01); A61B 5/7264 (2013.01); G06F 3/0482 (2013.01); G06F 3/0484 (2013.01); G06F 9/542 (2013.01); G06F 16/245 (2019.01); G06F 21/6254 (2013.01); G06K 9/2063 (2013.01); G06K 9/6231 (2013.01); G06K 9/6254 (2013.01); G06K 9/6256 (2013.01); G06K 9/6262 (2013.01); G06K 9/6277 (2013.01); G06N 5/04 (2013.01); G06N 5/045 (2013.01); G06N 20/00 (2019.01); G06N 20/20 (2019.01); G06Q 10/06315 (2013.01); G06Q 20/14 (2013.01); G06T 3/40 (2013.01); G06T 5/002 (2013.01); G06T 5/008 (2013.01); G06T 5/50 (2013.01); G06T 7/0012 (2013.01); G06T 7/0014 (2013.01); G06T 7/10 (2017.01); G06T 7/11 (2017.01); G06T 7/187 (2017.01); G06T 7/44 (2017.01); G06T 7/97 (2017.01); G06T 11/001 (2013.01); G06T 11/006 (2013.01); G06T 11/206 (2013.01); G16H 10/20 (2018.01); G16H 15/00 (2018.01); G16H 30/20 (2018.01); G16H 30/40 (2018.01); G16H 40/20 (2018.01); G16H 50/20 (2018.01); H04L 67/12 (2013.01); H04L 67/42 (2013.01); A61B 5/055 (2013.01); A61B 6/032 (2013.01); A61B 6/5217 (2013.01); A61B 8/4416 (2013.01); G06F 40/295 (2020.01); G06K 9/6229 (2013.01); G06K 9/6267 (2013.01); G06K 9/66 (2013.01); G06K 2209/05 (2013.01); G06Q 50/22 (2013.01); G06T 7/70 (2017.01); G06T 2200/24 (2013.01); G06T 2207/10048 (2013.01); G06T 2207/10081 (2013.01); G06T 2207/10088 (2013.01); G06T 2207/10116 (2013.01); G06T 2207/10132 (2013.01); G06T 2207/20076 (2013.01); G06T 2207/20081 (2013.01); G06T 2207/20084 (2013.01); G06T 2207/30004 (2013.01); G06T 2207/30008 (2013.01); G06T 2207/30016 (2013.01); G06T 2207/30061 (2013.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01);
Abstract

An automatic patient recruitment system is operable to determine a set of eligibility criteria, which includes abnormality criteria and other patient criteria, for each of a plurality of pharmaceutical studies. Abnormality data is generated for received medical scans by performing at least one inference function on image data of each medical scans by utilizing a computer vision model trained on a training set of medical scans. One of a plurality of patients is identified to be eligible for a pharmaceutical study by determining a medical scan of the patient has abnormality data that compares favorably to the abnormality criteria of the pharmaceutical study and by determining that the patient has patient data that compares favorably to the other patient criteria of the pharmaceutical study. A notification indicating the identified patient is eligible for the pharmaceutical study is generated for transmission to a client device.


Find Patent Forward Citations

Loading…